Andreas Papas, an adjunct professor at East Tennessee State University and CEO of Antares Health Products, delivered a presentation on the applications of Vitamin E TPGS. He began by acknowledging the advancements in mRNA technology, particularly in vaccines and gene therapy, but highlighted the challenges associated with its oral administration due to its large molecular size and stability issues. Papas explained that mRNA therapies are typically administered parenterally and face challenges in targeted delivery and efficacy.
Papas introduced Vitamin E TPGS, a derivative of natural D-alpha tocopherol, as a potential solution to these challenges. He detailed its properties, including its amphiphilic nature, which allows it to form micellar components and nanoparticles. This characteristic made it suitable for enhancing the stability and bioavailability of mRNA therapies. He also discussed the antioxidant properties of mixed tocopherols, which are used in food and pharmaceutical industries to maintain lipid stability.
Papas highlighted the historical use of Vitamin E TPGS in treating malabsorption issues in children with cholestasis and cystic fibrosis. He noted that it not only corrected Vitamin E deficiency but also enhanced the absorption of other fat-soluble vitamins. This led to its extensive study and application in drug formulations to increase absorption and bioavailability.
The presentation also covered the role of Vitamin E TPGS in enhancing the encapsulation activity and controlled release in drug delivery systems, including liposomes and nanoliposomes. Papas emphasised its stability and ability to prevent oxidation, which is crucial for maintaining the efficacy of mRNA therapies. He mentioned its use in various drug formulations, including HIV protease inhibitors and hepatitis drugs, and its potential in mRNA therapies due to its safety and biocompatibility.
